StockNews.com assumed coverage on shares of Avinger (NASDAQ:AVGR – Free Report) in a report released on Tuesday morning. The brokerage issued a hold rating on the medical device company’s stock.
Avinger Trading Up 24.0 %
Shares of NASDAQ AVGR opened at $1.29 on Tuesday. Avinger has a twelve month low of $0.90 and a twelve month high of $6.55. The stock has a fifty day simple moving average of $1.15 and a 200-day simple moving average of $2.18. The stock has a market capitalization of $2.20 million, a PE ratio of -0.07 and a beta of 1.17.
Avinger (NASDAQ:AVGR – Get Free Report) last released its earnings results on Thursday, August 8th. The medical device company reported ($2.82) EPS for the quarter, missing the consensus estimate of ($0.43) by ($2.39). The company had revenue of $1.85 million during the quarter, compared to analysts’ expectations of $2.55 million. On average, equities analysts predict that Avinger will post -4.69 earnings per share for the current year.
Institutional Trading of Avinger
Avinger Company Profile
Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.
Recommended Stories
- Five stocks we like better than Avinger
- Are Penny Stocks a Good Fit for Your Portfolio?
- When Is the Best Time to Invest in Mutual Funds?
- Canadian Penny Stocks: Can They Make You Rich?
- Is NVIDIA Stock in a Correction or Consolidation?
- What to Know About Investing in Penny Stocks
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for Avinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avinger and related companies with MarketBeat.com's FREE daily email newsletter.